[P1-6-7] Long-term safety of pegvisomant in patients with acromegaly followed in ACROSTUDY
○R Gomez1, J van der Lans-Bussemaker1, J Hey-Hadavi2, N Rajicic2, CJ Strasburger3, AJ van der Lely4(1.Pfizer Ltd, UK, 2.Pfizer New York, USA, 3.Charite Universitatsmedizin, Campus Mitte Berlin, Germany, 4.Erasmus University Medical Center, Netherlands)